(Q64055605)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

2 references

13 November 2020

8 February 2021

Clinical development of targeted and immune based anti-cancer therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

0 references

1 reference

13 November 2020

1 reference

8 February 2021

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

author name string

N A Seebacher

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

A E Stacy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

G M Porter

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

publication date

11 April 2019

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

13 November 2020

8 February 2021

Journal of Experimental & Clinical Cancer Research

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

9 September 2020

13 November 2020

8 February 2021

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

page(s)

156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

3 May 2020

copyright license

2 references

13 November 2020

Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro

8 February 2021

cites work

1 reference

12 December 2020

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules.

1 reference

12 December 2020

Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins

1 reference

12 December 2020

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

1 reference

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

1 reference

12 December 2020

Two EGF molecules contribute additively to stabilization of the EGFR dimer

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

1 reference

12 December 2020

Combinatorial chemoprevention of intestinal neoplasia

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Cell signaling by receptor tyrosine kinases

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Oncogenic kinase signalling

1 reference

12 December 2020

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor

1 reference

12 December 2020

Phase I and II clinical trials of trastuzumab

1 reference

12 December 2020

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

EGFR-mediated cell cycle regulation.

1 reference

12 December 2020

Mutations of the BRAF gene in human cancer

1 reference

12 December 2020

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 December 2020

Microscopic residual disease is a risk factor in the primary treatment of breast cancer

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

1 reference

12 December 2020

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

12 December 2020

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

1 reference

12 December 2020

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

1 reference

12 December 2020

Mechanism of action of erbB tyrosine kinase inhibitors

1 reference

12 December 2020

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

1 reference

12 December 2020

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 December 2020

The biology of VEGF and its receptors

1 reference

12 December 2020

Gefitinib (Iressa) trials in non-small cell lung cancer

1 reference

12 December 2020

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

1 reference

12 December 2020

Classical chemotherapy: mechanisms, toxicities and the therapeutic window

1 reference

12 December 2020

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

1 reference

12 December 2020

Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors

1 reference

12 December 2020

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

12 December 2020

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

The RAF proteins take centre stage

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

12 December 2020

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

12 December 2020

The B7 family revisited

1 reference

12 December 2020

EGFR mutation and response of lung cancer to gefitinib

1 reference

12 December 2020

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

1 reference

12 December 2020

FDA drug approval summary: erlotinib (Tarceva) tablets

1 reference

12 December 2020

Drug-conjugated monoclonal antibodies for the treatment of cancer

1 reference

12 December 2020

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

VEGF as a key mediator of angiogenesis in cancer

1 reference

12 December 2020

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

12 December 2020

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

1 reference

12 December 2020

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

12 December 2020

Clinical experience with gefitinib: an update

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Back to the roots: the remarkable RAF oncogene story

1 reference

12 December 2020

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

1 reference

12 December 2020

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

1 reference

12 December 2020

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

12 December 2020

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

1 reference

12 December 2020

Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.

1 reference

12 December 2020

Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer

1 reference

12 December 2020

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events

1 reference

12 December 2020

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

1 reference

12 December 2020

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

1 reference

12 December 2020

ERK implication in cell cycle regulation

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2

1 reference

12 December 2020

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

1 reference

12 December 2020

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

12 December 2020

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

1 reference

12 December 2020

Trastuzumab--mechanism of action and use in clinical practice

1 reference

12 December 2020

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

12 December 2020

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

1 reference

12 December 2020

Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

1 reference

12 December 2020

Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.

1 reference

12 December 2020

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

1 reference

12 December 2020

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

1 reference

12 December 2020

EGFR antagonists in cancer treatment

1 reference

12 December 2020

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

12 December 2020

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

12 December 2020

Detection of BRAF V600E mutation by pyrosequencing

1 reference

12 December 2020

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

12 December 2020

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

1 reference

12 December 2020

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

1 reference

12 December 2020

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

12 December 2020

1 reference

12 December 2020

The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl

1 reference

12 December 2020

Monoclonal antibodies for cancer immunotherapy

1 reference

12 December 2020

Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors

1 reference

12 December 2020

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

1 reference

12 December 2020

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

1 reference

12 December 2020

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

12 December 2020

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

1 reference

12 December 2020

Systemic effects of local radiotherapy

1 reference

12 December 2020

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

12 December 2020

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects

1 reference

12 December 2020

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

12 December 2020

Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects

1 reference

12 December 2020

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

1 reference

12 December 2020

Oncogenic EGFR signaling networks in glioma

1 reference

12 December 2020

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

1 reference

12 December 2020

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

1 reference

12 December 2020

A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models

1 reference

12 December 2020

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

1 reference

12 December 2020

PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells

1 reference

12 December 2020

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

12 December 2020

Angiogenesis inhibitors: current strategies and future prospects

1 reference

12 December 2020

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

12 December 2020

RAF protein-serine/threonine kinases: Structure and regulation

1 reference

12 December 2020

1 reference

12 December 2020

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

12 December 2020

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

1 reference

12 December 2020

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

12 December 2020

EGFR and KRAS in colorectal cancer

1 reference

12 December 2020

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

1 reference

12 December 2020

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

12 December 2020

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

1 reference

12 December 2020

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

1 reference

12 December 2020

Hallmarks of Cancer: The Next Generation

1 reference

12 December 2020

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

1 reference

12 December 2020

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

1 reference

12 December 2020

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients

1 reference

12 December 2020

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

1 reference

12 December 2020

Irreversible protein kinase inhibitors

1 reference

12 December 2020

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

1 reference

12 December 2020

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

1 reference

12 December 2020

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype

1 reference

12 December 2020

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

12 December 2020

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

12 December 2020

BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance

1 reference

12 December 2020

Small molecule inhibitors of BRAF in clinical trials

1 reference

12 December 2020

Targeting the EGFR signaling pathway in cancer therapy

1 reference

12 December 2020

A preclinical and clinical review of aflibercept for the management of cancer

1 reference

12 December 2020

Cancer and radiation therapy: current advances and future directions

1 reference

12 December 2020

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

Discovery of small molecule cancer drugs: successes, challenges and opportunities

1 reference

12 December 2020

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

1 reference

12 December 2020

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

1 reference

12 December 2020

The BATTLE trial: personalizing therapy for lung cancer

1 reference

12 December 2020

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

1 reference

12 December 2020

1 reference

12 December 2020

Trastuzumab: updated mechanisms of action and resistance in breast cancer

1 reference

12 December 2020

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis

1 reference

12 December 2020

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

1 reference

12 December 2020

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

1 reference

12 December 2020

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

12 December 2020

Pertuzumab: new hope for patients with HER2-positive breast cancer

1 reference

12 December 2020

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

12 December 2020

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

1 reference

12 December 2020

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

1 reference

12 December 2020

Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance

1 reference

12 December 2020

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers

1 reference

12 December 2020

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model

1 reference

12 December 2020

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.

1 reference

12 December 2020

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

12 December 2020

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer

1 reference

12 December 2020

BRAF inhibitors in clinical oncology

1 reference

12 December 2020

Clinicopathological relevance of BRAF mutations in human cancer

1 reference

12 December 2020

1 reference

12 December 2020

B-Raf and the inhibitors: from bench to bedside

1 reference

12 December 2020

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

1 reference

12 December 2020

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

12 December 2020

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

1 reference

12 December 2020

Systemic cancer therapy: achievements and challenges that lie ahead

1 reference

12 December 2020

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

12 December 2020

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

1 reference

12 December 2020

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

1 reference

12 December 2020

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

12 December 2020

The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab).

1 reference

12 December 2020

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

1 reference

12 December 2020

Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.

1 reference

12 December 2020

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

1 reference

12 December 2020

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

1 reference

12 December 2020

B-Raf mutation: a key player in molecular biology of cancer.

1 reference

12 December 2020

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.

1 reference

12 December 2020

Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations

1 reference

12 December 2020

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

1 reference

12 December 2020

BRAF inhibitors: From the laboratory to clinical trials

1 reference

12 December 2020

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

1 reference

12 December 2020

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

12 December 2020

Dabrafenib for treatment of BRAF-mutant melanoma

1 reference

12 December 2020

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

1 reference

12 December 2020

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

1 reference

12 December 2020

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

1 reference

12 December 2020

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

1 reference

12 December 2020

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

1 reference

12 December 2020

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

1 reference

12 December 2020

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

12 December 2020

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

1 reference

12 December 2020

Imatinib: a breakthrough of targeted therapy in cancer

1 reference

12 December 2020

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

12 December 2020

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

12 December 2020

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies

1 reference

12 December 2020

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

1 reference

12 December 2020

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

12 December 2020

Colorectal cancer in Chinese patients: current and emerging treatment options.

1 reference

12 December 2020

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

1 reference

12 December 2020

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)

1 reference

12 December 2020

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

12 December 2020

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

1 reference

12 December 2020

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

1 reference

12 December 2020

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

1 reference

12 December 2020

Human PD-1 binds differently to its human ligands: a comprehensive modeling study

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

KRAS as a Therapeutic Target

1 reference

12 December 2020

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

12 December 2020

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

1 reference

12 December 2020

Profile of neratinib and its potential in the treatment of breast cancer

1 reference

12 December 2020

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

1 reference

12 December 2020

Bevacizumab induces A549 cell apoptosis through the mechanism of endoplasmic reticulum stress in vitro.

1 reference

12 December 2020

Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells

1 reference

12 December 2020

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

1 reference

12 December 2020

Management of regorafenib-related toxicities: a review

1 reference

12 December 2020

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

1 reference

12 December 2020

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence

1 reference

12 December 2020

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

1 reference

12 December 2020

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

1 reference

12 December 2020

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance

1 reference

12 December 2020

Second- and third-generation ALK inhibitors for non-small cell lung cancer

1 reference

12 December 2020

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

12 December 2020

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

1 reference

12 December 2020

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

1 reference

12 December 2020

Reversing T-cell Dysfunction and Exhaustion in Cancer

1 reference

12 December 2020

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

1 reference

12 December 2020

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

1 reference

12 December 2020

Evolution of ramucirumab in the treatment of cancer - A review of literature

1 reference

12 December 2020

Olmutinib: First Global Approval.

1 reference

12 December 2020

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.

1 reference

12 December 2020

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

1 reference

12 December 2020

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

1 reference

12 December 2020

Immuno-oncology combinations: raising the tail of the survival curve

1 reference

12 December 2020

The role of regulatory T cells in cancer immunology

1 reference

12 December 2020

The role of the ALK receptor in cancer biology

1 reference

12 December 2020

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

12 December 2020

Clinical potential of necitumumab in non-small cell lung carcinoma

1 reference

12 December 2020

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

1 reference

12 December 2020

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

1 reference

12 December 2020

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

1 reference

12 December 2020

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

1 reference

12 December 2020

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

1 reference

12 December 2020

Necitumumab for the treatment of squamous cell non-small cell lung cancer.

1 reference

12 December 2020

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

1 reference

12 December 2020

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

1 reference

12 December 2020

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

1 reference

12 December 2020

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

1 reference

12 December 2020

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

1 reference

12 December 2020

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

1 reference

12 December 2020

PharmGKB summary: sorafenib pathways

1 reference

12 December 2020

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

1 reference

12 December 2020

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management

1 reference

12 December 2020

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy

1 reference

12 December 2020

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

12 December 2020

Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers

1 reference

12 December 2020

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

12 December 2020

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

1 reference

12 December 2020

BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis

1 reference

12 December 2020

Durvalumab: First Global Approval

1 reference

12 December 2020

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

1 reference

12 December 2020

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

1 reference

12 December 2020

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.

1 reference

12 December 2020

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

1 reference

12 December 2020

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

1 reference

12 December 2020

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

1 reference

12 December 2020

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

1 reference

12 December 2020

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

1 reference

12 December 2020

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

1 reference

12 December 2020

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy

1 reference

12 December 2020

Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer

1 reference

12 December 2020

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies

1 reference

12 December 2020

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

1 reference

12 December 2020

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.

1 reference

12 December 2020

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

1 reference

12 December 2020

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

1 reference

12 December 2020

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

1 reference

12 December 2020

Characterization of Covalent-Reversible EGFR Inhibitors.

1 reference

12 December 2020

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

1 reference

12 December 2020

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

1 reference

12 December 2020

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

1 reference

12 December 2020

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

1 reference

12 December 2020

10.1186/S13046-019-1094-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 May 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30975211%20AND%20SRC:MED&resulttype=core&format=json

3 May 2020

PubMed publication ID

30975211

1 reference